NASDAQ · Medical - Care Facilities

COMPASS Pathways plc (CMPS) Stock

$13.31 -0.60% NASDAQ: CMPS Healthcare

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments.

Valuation

MetricValue
Price$13.31
Market Cap$1.28B
P/E Ratio-6.19
P/B Ratio4.48
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$15.40
52-Week Low$3.50
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-150.89%
ROA-33.62%
ROCE-45.60%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio3.32

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-83.0M$-110.0M$-137.0M$-178.0M$-179.0M
Net Profit$-72.0M$-92.0M$-118.0M$-155.0M$-288.0M
EPS$-1.79$-2.16$-2.32$-2.30$-3.08
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$301.0M$197.0M$276.0M$214.0M$210.0M
Total Liabilities$16.0M$16.0M$50.0M$59.0M$263.0M
Cash$273.0M$143.0M$220.0M$165.0M$150.0M
Borrowings$4.0M$2.0M$33.0M$32.0M$21.0M

Latest News

Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies Proactive · Jul 15, 2026 Is COMPASS Pathways plc (CMPS) Stock a Psychedelic Medicine Opportunity After Positive COMP360 Data? Insider Monkey · Jul 15, 2026 The Race to Commercialize the World’s Most Powerful Psychedelic WSJ · Jul 14, 2026 Weekly Roundup on the Cannabis Sector & Psychedelic Sector Market Exclusive · Jul 13, 2026 Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says Proactive · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-68.0M$-105.0M$-97.0M$-119.0M$-157.0M
Investing Cash Flow$-1.0M$-1.0M$0$0$0
Financing Cash Flow$2.0M$1.0M$-1.0M$38.0M$0
Net Cash Flow$83.0M$-130.0M$77.0M$-55.0M$-15.0M
Free Cash Flow$-68.0M$-106.0M$-97.0M$-119.0M$-157.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.16
EV / EBITDA-4.62
FCF Yield-12.47%
Quick Ratio3.32
Interest Coverage-35.54
Return 1Y153.46%
Return 3Y34.14%
Return 5Y-61.99%

Ownership

Insiders Held7.83%
Institutions Held72.45%
Institutions Float Held78.60%
Institutional HolderSharesReport Date
Deep Track Capital, Lp12,161,4962026-03-31
RTW Investments LP10,632,3902026-03-31
Marshall Wace LLP4,038,3352026-03-31
Tang Capital Management, LLC4,002,2002026-03-31
BIT Capital GmbH3,491,2342026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AVNS $24.99 +0.04% 19.96 $1.17B 0.00%
CYHCommunity Health Systems, Inc. $2.70 -1.10% -1.21 $380.48M 0.00%
EHABEnhabit Inc $13.80 +0.07% -153.33 $706.91M 0.00%
FDMT $10.09 -0.88% -3.47 $527.47M 0.00%
GOSSGossamer Bio, Inc. $0.19 +38.24% -0.17 $44.10M 0.00%

About COMPASS Pathways plc

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

COMPASS Pathways plc is headquartered in GB.

COMPASS Pathways plc (CMPS) stock trades at $13.31 with a market capitalization of $1.28B. The stock is valued at a price-to-earnings (P/E) ratio of -6.19, price-to-book of 4.48, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.50 and $15.40, and currently trades 13.6% below its 52-week high.

On profitability, COMPASS Pathways plc generates a return on equity (ROE) of -150.89%, return on capital employed of -45.60%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: compasspathways.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides